Literature DB >> 33556366

Noncanonical Functions of the Polycomb Group Protein EZH2 in Breast Cancer.

Talha Anwar1, Maria E Gonzalez2, Celina G Kleer3.   

Abstract

Enhancer of Zeste Homologue 2 (EZH2) is the catalytic subunit of the polycomb repressive complex 2 (PRC2) that is critical for determining cell identity. An epigenetic writer, EZH2 has a well-defined role in transcriptional repression by depositing trimethyl marks on lysine 27 of histone H3. However, there is mounting evidence that histone methyltransferases like EZH2 exert histone methyltransferase-independent functions. The relevance of these functions to breast cancer progression and their regulatory mechanisms are only beginning to become understood. Here, we review the current understanding of EZH2 H3K27me3-independent, noncanonical, functions and their regulation in breast cancer.
Copyright © 2021 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33556366      PMCID: PMC8127103          DOI: 10.1016/j.ajpath.2021.01.013

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  98 in total

Review 1.  Epigenetic protein families: a new frontier for drug discovery.

Authors:  Cheryl H Arrowsmith; Chas Bountra; Paul V Fish; Kevin Lee; Matthieu Schapira
Journal:  Nat Rev Drug Discov       Date:  2012-04-13       Impact factor: 84.694

2.  Control of developmental regulators by Polycomb in human embryonic stem cells.

Authors:  Tong Ihn Lee; Richard G Jenner; Laurie A Boyer; Matthew G Guenther; Stuart S Levine; Roshan M Kumar; Brett Chevalier; Sarah E Johnstone; Megan F Cole; Kyo-ichi Isono; Haruhiko Koseki; Takuya Fuchikami; Kuniya Abe; Heather L Murray; Jacob P Zucker; Bingbing Yuan; George W Bell; Elizabeth Herbolsheimer; Nancy M Hannett; Kaiming Sun; Duncan T Odom; Arie P Otte; Thomas L Volkert; David P Bartel; Douglas A Melton; David K Gifford; Rudolf Jaenisch; Richard A Young
Journal:  Cell       Date:  2006-04-21       Impact factor: 41.582

3.  The methyltransferase Ezh2 controls cell adhesion and migration through direct methylation of the extranuclear regulatory protein talin.

Authors:  Merry Gunawan; Nandini Venkatesan; Jia Tong Loh; Jong Fu Wong; Heidi Berger; Wen Hao Neo; Liang Yao Jackson Li; Myint Khun La Win; Yin Hoe Yau; Tiannan Guo; Peter Chi Ee See; Sayuri Yamazaki; Keh Chuang Chin; Alexandre R Gingras; Susana Geifman Shochat; Lai Guan Ng; Siu Kwan Sze; Florent Ginhoux; I-hsin Su
Journal:  Nat Immunol       Date:  2015-03-09       Impact factor: 25.606

4.  Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function.

Authors:  Lixin Wan; Kexin Xu; Yongkun Wei; Jinfang Zhang; Tao Han; Christopher Fry; Zhao Zhang; Yao Vickie Wang; Liyu Huang; Min Yuan; Weiya Xia; Wei-Chao Chang; Wen-Chien Huang; Chien-Liang Liu; Yuan-Ching Chang; Jinsong Liu; Yun Wu; Victor X Jin; Xiangpeng Dai; Jianfeng Guo; Jia Liu; Shulong Jiang; Jin Li; John M Asara; Myles Brown; Mien-Chie Hung; Wenyi Wei
Journal:  Mol Cell       Date:  2018-01-18       Impact factor: 17.970

5.  Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes.

Authors:  Karolina Holm; Dorthe Grabau; Kristina Lövgren; Steina Aradottir; Sofia Gruvberger-Saal; Jillian Howlin; Lao H Saal; Stephen P Ethier; Pär-Ola Bendahl; Olle Stål; Per Malmström; Mårten Fernö; Lisa Rydén; Cecilia Hegardt; Åke Borg; Markus Ringnér
Journal:  Mol Oncol       Date:  2012-06-20       Impact factor: 6.603

6.  Invasive breast carcinomas in Ghana: high frequency of high grade, basal-like histology and high EZH2 expression.

Authors:  Judy Pang; Kathy A Toy; Ken A Griffith; Baffour Awuah; Solomon Quayson; Lisa A Newman; Celina G Kleer
Journal:  Breast Cancer Res Treat       Date:  2012-04-13       Impact factor: 4.872

7.  Downregulation of Ezh2 methyltransferase by FOXP3: new insight of FOXP3 into chromatin remodeling?

Authors:  Zhu Shen; Ling Chen; Xiaojun Yang; Yun Zhao; Eric Pier; Xia Zhang; Xichuan Yang; Ya Xiong
Journal:  Biochim Biophys Acta       Date:  2013-05-17

8.  EZH2 protein expression in normal breast epithelium and risk of breast cancer: results from the Nurses' Health Studies.

Authors:  Francisco Beca; Kevin Kensler; Benjamin Glass; Stuart J Schnitt; Rulla M Tamimi; Andrew H Beck
Journal:  Breast Cancer Res       Date:  2017-03-02       Impact factor: 6.466

9.  Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1.

Authors:  M E Gonzalez; X Li; K Toy; M DuPrie; A C Ventura; M Banerjee; M Ljungman; S D Merajver; C G Kleer
Journal:  Oncogene       Date:  2008-12-15       Impact factor: 9.867

10.  An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation.

Authors:  George P Souroullas; William R Jeck; Joel S Parker; Jeremy M Simon; Jie-Yu Liu; Joshiawa Paulk; Jessie Xiong; Kelly S Clark; Yuri Fedoriw; Jun Qi; Christin E Burd; James E Bradner; Norman E Sharpless
Journal:  Nat Med       Date:  2016-05-02       Impact factor: 53.440

View more
  3 in total

1.  Targeting Triple-Negative Breast Cancer by a Novel Proteolysis Targeting Chimera Degrader of Enhancer of Zeste Homolog 2.

Authors:  Brandon Dale; Chris Anderson; Kwang-Su Park; H Ümit Kaniskan; Anqi Ma; Yudao Shen; Chengwei Zhang; Ling Xie; Xian Chen; Xufen Yu; Jian Jin
Journal:  ACS Pharmacol Transl Sci       Date:  2022-06-24

2.  EZH2 Protein Expression in Estrogen Receptor Positive Invasive Breast Cancer Treated With Neoadjuvant Endocrine Therapy: An Exploratory Study of Association With Tumor Response.

Authors:  Yujun Gan; Yungtai Lo; Della Makower; Celina Kleer; Jinyu Lu; Susan Fineberg
Journal:  Appl Immunohistochem Mol Morphol       Date:  2022-09-02

3.  Proteomic and molecular dynamic investigations of PTM-induced structural fluctuations in breast and ovarian cancer.

Authors:  Dmitry Tikhonov; Liudmila Kulikova; Arthur T Kopylov; Vladimir Rudnev; Alexander Stepanov; Kristina Malsagova; Alexander Izotov; Dmitry Kulikov; Alexey Zulkarnaev; Dmitry Enikeev; Natalia Potoldykova; Anna L Kaysheva
Journal:  Sci Rep       Date:  2021-09-29       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.